Chemical formula: C₉H₁₁NO₅ Molecular mass: 213.189 g/mol PubChem compound: 92974
Droxidopa is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopa-decarboxylase, which is extensively distributed throughout the body. Droxidopa is believed to exert its pharmacological effects through norepinephrine and not through the parent molecule or other metabolites. The exact mechanism of action of droxidopa in the treatment of neurogenic orthostatic hypotension is unknown.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C01CA27 | C Cardiovascular system → C01 Cardiac therapy → C01C Cardiac stimulants excl. cardiac glycosides → C01CA Adrenergic and dopaminergic agents | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| NORTHERA Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Droxidopa is an active ingredient of these brands:
United States (US)Japan (JP)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
